CMAHP
Inactive cytidine monophosphate-N-acetylneuraminic acid hydroxylase
Also known as: CMAH_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for CMAHP in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
501 residues, UniProt reviewed canonical sequence.
>Q9Y471|CMAHP
1 MDENNGLLLL ELNPPNPWDL QPRSPEELAF GEVQITYLTH ACMDLKLGDK RMVFDPWLIG
61 PAFARGWWLL HEPPSDWLER LCQADLIYIS HLHSDHLSYP TLKKLAGRRP DIPIYVGNTE
121 RPVFWNLNQS GVQLTNINVV PFGIWQQVDK NLRFMILMDG VHPEMDTCII VEYKGHKILN
181 IVDCTRPNGG RLPMKVALMM SDFAGGASGF PMTFSGGKFT EEWKAQFIKT ERKKLLNYKA
241 RLVKNLQPRI YCPFAGYFVE SHPSDKYIKE TNTKNDPNEL NNLIKKNSDV ITWTPRPGAT
301 LDLGRMLKDR TDSKGIIEPP EGTKIYKDSW DFEPYLEILN AALGDEIFLH SSWIKEYFTW
361 AGFKDYNLVV RMIETDEDFN PFPGGYDYLV DFLDLSFPKE RPQREHPYEE IHSRVDVIRH
421 VVKNGLLWDE LYIGFQTRLQ RDPDIYHHLF WNHFQIKLPL TPPNWKSFLM CCEQNGPVIL
481 QFSTERTNEP NRNKFSVENK ALocalizationUniProt · AlphaFold · HPA
Whether an antibody against CMAHP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- regulation of Wnt signaling pathway
- CMP-N-acetylneuraminate metabolic process
Molecular functions
- CMP-N-acetylneuraminate monooxygenase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Ribonuclease Z/Hydroxyacylglutathione hydrolase-like
- Cytidine monophosphate-N-acetylneuraminic acid hydroxylase
- Beta-lactamase superfamily domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CMAHP as an antibody target. Whether an autoantibody or antibody against CMAHP could matter depends on whether native CMAHP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CMAHP is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CMAHP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...